Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States

Antiviral Research

Volumn 93, Issue 3, 2012, Pages 381-386

  Nguyen, Ha T ^a,c,d   Trujillo, Alma A ^a   Sheu, Tiffany G ^a,d   Levine, Marnie ^a,d   Mishin, Vasiliy P ^a   Shaw, Michael ^a   Ades, Edwin W ^b   Klimov, Alexander I ^a   Fry, Alicia M ^a   Gubareva, Larisa V ^a  

^a Influenza Division   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

^d BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

H275Y; I223K; I223R; Neuraminidase inhibition assay; Neuraminidase inhibitor; Pandemic H1N1; Pyrosequencing

Indexed keywords

LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

2009 H1N1 INFLUENZA; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; GENETIC VARIABILITY; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INFLUENZA VIRUS; INTENSIVE CARE UNIT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PYROSEQUENCING; SUBSTITUTION REACTION; UNITED STATES; VIRUS ISOLATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; PANDEMICS; UNITED STATES; VIRAL PROTEINS;

ORTHOMYXOVIRIDAE;

EID: 84857333256     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.01.006     Document Type: Article

References (21)

1. Bautista E., Chotpitayasunondh T., Gao Z., Harper S.A., Shaw M., Uyeki T.M., Zaki S.R., Hayden F.G., Hui D.S., Kettner J.D., Kumar A., Lim M., Shindo N., Penn C., Nicholson K.G. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 2010, 362:1708-1719.
2. Update: Influenza activity - United States, 2010-11 season, and composition of the 2011-12 influenza vaccine. Morb. Mortal. Wkly. Rep. 2011, 60:705-712. Centers for Disease Control and Prevention (CDC).
3. Chen L.F., Dailey N.J., Rao A.K., Fleischauer A.T., Greenwald I., Deyde V.M., Moore Z.S., Anderson D.J., Duffy J., Gubareva L.V., Sexton D.J., Fry A.M., Srinivasan A., Wolfe C.R. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J. Infect. Dis. 2011, 203:838-846.
4. Deyde V.M., Sheu T.G., Trujillo A.A., Okomo-Adhiambo M., Garten R., Klimov A.I., Gubareva L.V. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob. Agents Chemother. 2010, 54:1102-1110.
5. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., St George K., Epperson S., Brammer L., Klimov A.I., Bresee J.S., Fry A.M. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009, 301:1034-1041.
6. Graitcer S.B., Gubareva L., Kamimoto L., Doshi S., Vandermeer M., Louie J., Waters C., Moore Z., Sleeman K., Okomo-Adhiambo M., Marshall S.A., St.George K., Pan C.Y., LaPlante J.M., Klimov A., Fry A.M. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg. Infect. Dis. 2011, 17:255-257.
7. Gubareva L.V., Trujillo A.A., Okomo-Adhiambo M., Mishin V.P., Deyde V.M., Sleeman K., Nguyen H.T., Sheu T.G., Garten R.J., Shaw M.W., Fry A.M., Klimov A.I. Comprehensive assessment of 2009 pandemic influenza A(H1N1) virus drug susceptibility in vitro. Antivir. Ther. 2010, 15:1151-1159.
8. Harvala H., Gunson R., Simmonds P., Hardie A., Bennett S., Scott F., Roddie H., McKnight J., Walsh T., Rowney D., Clark A., Bremner J., Aitken C., Templeton K. The emergence of oseltamivir-resistant pandemic influenza A (H1N1) 2009 virus amongst hospitalized immunocompromised patients in Scotland, November-December, 2009. Euro. Surveill. 2010, 15:19536.
9. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold?. Clin. Infect. Dis. 2009, 48:S3-S13.
10. Lackenby A., Democratis J., Siqueira M.M., Zambon M.C. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir. Ther. 2008, 13:809-820.
11. Meijer A., Lackenby A., Hungnes O., Lina B., van-der-Werf S., Schweiger B., Opp M., Paget J., van-de-Kassteele J., Hay A., Zambon M. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 2009, 15:552-560.
12. Mehta T., McGrath E., Bheemreddy S., Salimnia H., Abdel-Haq N., Ang J.Y., Lum L., Chandrasekar P., Alangaden G.J. Detection of Oseltamivir Resistance During Therapy of 2009 H1N1 Influenza in Immunocompromised Patients: Utility of Cycle Threshold Values of Qualitative rRT-PCR. J ClinMicrobiol 2010, 48:4326-4328.
13. Nguyen H.T., Fry A.M., Loveless P.A., Klimov A.I., Gubareva L.V. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin. Infect. Dis. 2010, 51:983-984.
14. Nguyen H.T., Sheu T.G., Mishin V.P., Klimov A.I., Gubareva L.V. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother. 2010, 54:3671-3677.
15. Okomo-Adhiambo M., Demmler-Harrison G.J., Deyde V.M., Sheu T.G., Xu X., Klimov A.I., Gubareva L.V. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob. Agents Chemother. 2010, 54:1834-1841.
16. Okomo-Adhiambo M., Sleeman K., Ballenger K., Nguyen H.T., Mishin V.P., Sheu T.G., Smagala J., Li Y., Klimov A.I., Gubareva L.V. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2010, 2:2269-2289.
17. Operario D.J., Moser M.J., St.George K. Highly sensitive and quantitative detection of the H274Y oseltamivir resistance mutation in seasonal A/H1N1 influenza virus. J. Clin. Microbiol. 2010, 48:3517-3524.
18. Wang B., Dwyer D.E., Blyth C.C., Soedjono M., Shi H., Kesson A., Ratnamohan M., McPhie K., Cunningham A.L., Saksena N.K. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antiviral Res. 2010, 87:16-21.
19. Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010. Wkly. Epidemiol. Rec. 2010, 85:37-40. World Health Organization (WHO).
20. World Health Organization(WHO), 2011. Weekly update on oseltamivir resistance of influenza A (H1N1) 2009 virus 01 June 2011. Available athttp://www.who.int/csr/disease/influenza/2011_06_03_weekly_web_update_oseltamivir_resistance.pdf.
21. Yang J.R., Huang Y.P., Lin Y.C., Su C.H., Kuo C.Y., Hsu L.C., Wu H.S., Liu M.T. Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan. Antiviral. Res. 2010, 88:256-262.